views
So far, more than 100 different cannabinoidshave been identified, and there is a growing body of evidence supporting theclinical benefits of this class of compounds in treating the symptoms of a widevariety of chronic health conditions
Roots Analysis is pleased toannounce the publication of its recent study, titled, “Endocannabinoid System Targeted Therapeutics Market,2020-2030.“
The reportfeatures an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of endocannabinoid system targetingdrugs, over the next decade. The report features an in-depth analysis,highlighting the diverse capabilities of stakeholders engaged in this domain.In addition to other elements, the study includes:
§ A detailed assessment of the current marketlandscape of drug developers engaged in the development of endocannabinoidsystem targeted therapeutics.
§ Detailed profiles of developers of endocannabinoidsystem targeted therapeutics (shortlisted on the basis ofthe number of development programs).
§ An in-depth analysis of nearly 600 grants that have beenawarded to research institutes engaged in endocannabinoidsystem targeted therapeutics projects.
§ An analysis of the partnerships that have been establishedin this domain, in the recent past.
§ A detailed analysis of the various mergers and acquisitionsthat have taken place in this domain, between 2016-2020
§ An insightful chessboard analysis highlighting the mostpopular drug development strategies / paths adopted by various drug developersin the domain of endocannabinoid system targeted therapeutics.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
To request a sample copy / brochure of thisreport, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
§ TargetDisease Indication
§ Cancer
§ GeneticDisorders
§ NeurologicalIndications
§ Others
- Route of Administration
§ Oral
§ Inhalation
- Key Geographies
§ NorthAmerica
§ Europe
§ Asia-Pacific and the Rest of the World
Key companies covered inthe report
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tilray
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ Avicanna
§ GB Sciences
Formore information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Other Recent Offerings
1. Neoantigen TargetedTherapies Market, 2019-2030
2. Blood-Brain Barrier(BBB) Market (2nd Edition), 2020-2030: Focus onNon-Invasive Drug Delivery Technology Platforms and Therapeutics
3. Bispecific AntibodyTherapeutics Market (4th Edition),2019-2030
4. ContinuousManufacturing Market (Small Molecules andBiologics), 2020 – 2030
About Roots Analysis
RootsAnalysis is one of the fastest growing market research companies, sharing freshand independent perspectives in the bio-pharmaceutical industry. The in-depthresearch, analysis and insights are driven by an experienced leadership teamwhich has gained many years of significant experience in this sector. If you’d likehelp with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415